Ken Griffin Tempest Therapeutics, Inc. Call Options Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
Call Options
2 transactions
Others Institutions Holding TPST
# of Institutions
34Shares Held
1.43MCall Options Held
161KPut Options Held
78K-
Black Rock Inc. New York, NY508KShares$1.08 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA176KShares$373,5290.0% of portfolio
-
Geode Capital Management, LLC Boston, MA132KShares$280,0150.0% of portfolio
-
Fil LTD Hamilton, D0130KShares$274,7070.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX106KShares$223,8720.05% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $22.1M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...